Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 1, 2008, Pages 117-137

  Ribbing, Jakob ^a   Hooker, Andrew C ^a   Jonsson, E Niclas ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b F Hoffmann La Roche   (Switzerland)

Author keywords

Confirming; Data pooling; Learning; Meta analysis; Model selection; Population modelling; Population pharmacokinetics; Population optimal design; Predictive modelling

Indexed keywords

ANXIOLYTIC AGENT; CYTOCHROME P450 2E1;

ARTICLE; CLINICAL STUDY; DATA ANALYSIS; DRUG RESEARCH; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL;

EID: 41049090406     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9079-8     Document Type: Article

References (39)

1. Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H and Boissel JP (2000). Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?. J Pharm Sci 89(2): 155-167
2. Sheiner LB (1997). Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3): 275-291
3. Sheiner LB and Steimer JL (2000). Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40: 67-95
4. Jonsson EN and Sheiner LB (2002). More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther 72(6): 603-614
5. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang YN and Tandon V (2005). Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 7(3): E503-E512
6. Marshall S, Macintyre F, James I, Krams M and Jonsson NE (2006). Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development-A case study of a therapeutic protein. Clin Pharmacokinet 45(2): 177-197
7. Zhang L, Sinha V, Forgue ST, Callies S, Ni L and Peck R (2006). Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33(3): 369-393
8. Beal SL, Sheiner LB (1994) NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, San Francisco
9. Zingmark PH, Ekblom M, Odergren T, Ashwood T, Lyden P and Karlsson MO (2003). Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol 56(2): 173-183
10. Ribbing J and Jonsson EN (2004). Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 31(2): 109-134
11. Foracchia M, Hooker A, Vicini P and Ruggeri A (2004). POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74(1): 29-46
12. FDA (2006) Drug interaction studies-study design, data analysis, and implications for dosing and labeling ( http://www.fda.gov/cber/gdlns/ interactstud.htm )
13. Wade JR, Edholm M and Salmonson T (2005). A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J 7(2): 45
14. Zhou H (2006). Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?. J Clin Pharmacol 46(11): 1268-1289
15. MATLAB. In Version 7.0.1.24704 (R14) Service Pack 1 ed. Natick, MA, United States: MathWorks
16. Jonsson EN and Karlsson MO (1998). Automated covariate model building within NONMEM. Pharm Res 15(9): 1463-1468
17. Wahlby U, Jonsson EN and Karlsson MO (2001). Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28(3): 231-252
18. Lindbom L, Pihlgren P and Jonsson EN (2005). PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3): 241-257
19. Lindbom L, Ribbing J and Jonsson EN (2004). Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2): 85-94
20. Raab GM, Day S and Sales J (2000). How to select covariates to include in the analysis of a clinical trial. Control Clin Trials 21(4): 330-342
21. Harrell FE (2001) 4.1 Prespecification of predictor complexity without later simplification. In: Regression modeling strategies. Springer-Verlag, New York, pp. 53-56
22. Kerbusch T, Wahlby U, Milligan PA and Karlsson MO (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 56(6): 639-652
23. Hedges LV (1992). Meta-analysis. J Educ Stat 17(4, Special Issue: Meta Analysis): 279-296
24. Mosteller F and Colditz GA (1996). Understanding research synthesis (meta-analysis). Annu Rev Public Health 17: 1-23
25. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G and Sheiner LB (1996). A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2): 153-172
26. Sheiner LB and Beal SL (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4): 503-512
27. Van Houwelingen JC and le Cessie S (1990). Predictive value of statistical-models. Stat Med 9(11): 1303-1325
28. Waterhouse TH, Redmann S, Duffull SB and Eccleston JA (2005). Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn 32(3-4): 521-545
29. Altman DG and Andersen PK (1989). Bootstrap investigation of the stability of a Cox regression model. Stat Med 8(7): 771-783
30. Wakefield J (2000). The combination of population pharmacokinetic studies. Biometrics 56(1): 263-270
31. Wakefield J and Bennett J (1996). The Bayesian modeling of covariates for population pharmacokinetic models. J Am Stat Assoc 91(435): 917-927
32. Jonsson F, Jonsson EN, Bois FY and Marshall S (2007). The application of a Bayesian approach to the analysis of a complex, mechanistically based model. J Biopharm Stat 17(1): 65-92
33. Hoijtink H and Klugkist I (2007). Comparison of hypothesis testing and Bayesian model selection. Qual Quant 41(1): 73-91
34. Gisleskog PO, Karlsson MO and Beal SL (2002). Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29(5-6): 473-505
35. 5.7 Subgroups (1998) Interactions and Covariates. In: Products TEAftEoM (ed) Statistical principles for clinical trials. London, pp 28-29
36. Steyerberg EW, Eijkemans MJC, Harrell FE and Habbema JDF (2000). Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19(8): 1059-1079
37. Bonate PL (1999). The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 16(5): 709-717
38. Steyerberg EW, Eijkemans MJC, Lee KL, Habbema JDF and Houwelingen JC (2000). Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med 19(2): 141-160
39. Jonsson EN, Wade JR and Karlsson MO (1996). Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24(2): 245-263